Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Cardiovascular Effects of Oligomeric Procyanidins (OPCs) in Smokers

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
StatusasBaigta
Rėmėjai
Maastricht University Medical Center

Raktažodžiai

Santrauka

Smoking has been identified as a key risk factor for the development of cardiovascular diseases (CVD). It was found that a persistent increase in levels of oxidative stress and prolonged inflammation play a pivotal role in the pathogenesis of smoking associated CVD. Oligomeric proanthocyanidins (OPCs) are widely known for their anti-oxidant and anti-inflammatory effects, in vitro and in vivo. However, there are hardly any studies available that systematically investigated their acute and long-term effects on vascular function as well as on established biomarkers of oxidative stress and inflammation in an "at risk" population such as smokers.
Therefore, the aim of the present study is to investigate the effects of an eight-week supplementation with OPCs on vascular function as well as biomarkers of oxidative stress and inflammation in blood of smokers.

Datos

Paskutinį kartą patikrinta: 09/30/2011
Pirmasis pateikimas: 08/25/2008
Numatytas registravimas pateiktas: 08/25/2008
Pirmas paskelbtas: 08/26/2008
Paskutinis atnaujinimas pateiktas: 10/27/2011
Paskutinis atnaujinimas paskelbtas: 10/31/2011
Faktinė studijų pradžios data: 01/31/2009
Numatoma pirminio užbaigimo data: 10/31/2009
Numatoma studijų užbaigimo data: 10/31/2009

Būklė ar liga

Smoking

Intervencija / gydymas

Dietary Supplement: 2

Dietary Supplement: 1

Fazė

-

Rankų grupės

RankaIntervencija / gydymas
Placebo Comparator: 1
placebo
Dietary Supplement: 1
placebo
Active Comparator: 2
200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
Dietary Supplement: 2
200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks

Tinkamumo kriterijai

Amžius, tinkami studijuoti 30 Years Į 30 Years
Tinkamos studijoms lytysMale
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- healthy male subjects smoking ≥ 10 cigarettes per day with a regular smoking history of ≥ 5 years

- BMI ≥ 20 and ≤ 27 kg/m2

Exclusion Criteria:

- Occurence of any adverse event, in particular those which require the use of medication that might interfere with the effects and/or the uptake of the investigational products

- Intolerance of study products

- Occurence of a serious adverse event

- Use of supplements, functional foods and/or other products containing vitamins, antioxidants and polyphenolic compounds or other ingredients with potential influence on vessel function for at least one month before the beginning of the study and during the entire study

- Use of a medically prescribed diet or slimming diet

- Vegetarian or vegan lifestyle

- Excessive alcohol consumption (< 28 consumptions (approximately 250 g alcohol) per week)

- Participation in a clinical trial within 4 weeks before the study

- Non-compliance with the demands of the study

Rezultatas

Pirminės rezultatų priemonės

1. Vasoreactivity of conduit arteries by means of flow mediated dilation (FMD) [before start of intervention and at the end of the 8 week of intervention]

Antrinės rezultatų priemonės

1. Endothelium-dependent and -independent reactivity of microvasculature by means of Laser Doppler flowmetry (LDF) [before start of intervention, after 4 and 8 weeks of intervention]

2. Plasma nitrite and nitrate levels [before start of intervention, after 4 and 8 weeks of intervention]

3. Systemic oxidative stress markers such as plasma levels of PGF2alpha and TEAC, GSH erythrocyte levels and gene expression of redox enzymes [before start of intervention, after 4 and 8 weeks of intervention]

4. Systemic inflammation markers such as plasma levels of hsCRP, fibrinogen and cytokines, as well as gene expression levels of the latter [before start of intervention, after 4 and 8 weeks of intervention]

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge